Commonly Prescribed Medications Linked to Severe Progressive Bile Duct Injury: Study
A recent analysis published in the Indian Journal of Gastroenterology in February 2026 reveals a significant link between widely prescribed medications and progressive bile duct destruction. Demanding urgent clinical vigilance, an alarming 883 out of 889 reported cases were classified as severe.
Drug-induced vanishing bile duct syndrome (DI-VBDS) is a rare, severe cholestatic condition previously linked to NSAIDs and antiretrovirals only through isolated case reports. To address this evidence gap, Karkra et al. systematically analyzed global real-world data to identify the most frequent culprit medications and validate their statistical significance.
Therefore, the investigators analyzed 889 cases of the syndrome from over 30 million global FAERS reports spanning 2003 to 2024. Using reporting odds ratios (ROR), they defined a clinically significant risk signal as any medication linked to three or more events with an ROR greater than 1 (p < 0.05).
Key Clinical Findings of the analysis Includes:
Prevalent Causative Agent: The analysis found that ibuprofen was the most frequently reported medication, causing 11.24% of all cases with a significant ROR of 32.63.
Highest Risk Profile: The analysis demonstrated that the antiretroviral drug nevirapine carried the greatest statistical association, yielding a massive ROR of 119.01 while representing 4.89% of reports.
High Severity Rates: The analysis noted that an overwhelming 99.3% of the documented drug-induced cases were classified as severe, which alarmingly included an 18.6% mortality rate.
Common Antibiotic Triggers: The study highlighted profound antibiotic involvement, pointing out that sulfamethoxazole/trimethoprim and azithromycin presented dangerously high RORs of 63.23 and 59.21, respectively.
Demographic Susceptibility: The analysis revealed a relatively even sex distribution with 46.68% males and 42.63% females, alongside a notable 14.39% of incidents occurring in pediatric patients under 18 years of age.
The results suggest that several widely utilized therapeutic agents, prominently including ibuprofen and nevirapine, carry a statistically significant association with the development of vanishing bile duct syndrome, directly contributing to an 18.6% mortality risk among the 889 identified cases.
Thus, the analysis concludes healthcare professionals might consider maintaining a heightened clinical suspicion for these statistically linked medications when a patient presents with unexplained cholestatic liver injury, allowing for the cautious and permanent discontinuation of the suspected offending agent to gently prevent further disease progression.
While the reliance on an adverse event database inherently limits the ability to confirm definitive causality or definitively exclude alternative etiologies, these associative findings present a helpful foundation that could gently encourage future prospective investigations to better understand these adverse reactions.
Reference
Karkra, R., Goyal, R. M., Mohsen, M., Hajifathalian, K., & Al-Khazraji, A. (2026). Drug-induced vanishing bile duct syndrome: A real world pharmacovigilance study using the FDA adverse event reporting system. Indian Journal of Gastroenterology.
